Stock DCL CUU LONG PHARMACEUTICAL
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cuu Long Pharmaceutical

Equities

DCL

VN000000DCL1

Pharmaceuticals

End-of-day quote Ho Chi Minh S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
27,300 VND 0.00% Intraday chart for Cuu Long Pharmaceutical +5.00% +9.20%
Apr. 05 Cuu Long Pharmaceutical Joint Stock Company Announces Management Resignations CI
Jan. 29 Cuu Long Pharmaceutical Joint Stock Company Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 531,387 1,591,319 1,432,187 2,341,546 1,789,505 1,826,026
Enterprise Value (EV) 1 713,419 1,670,824 1,709,928 2,507,773 2,141,450 2,338,444
P/E ratio 42.4 x 22.5 x 26.1 x 26.6 x 15.4 x 29.6 x
Yield - - - - - -
Capitalization / Revenue 0.66 x 2.12 x 2.13 x 3.33 x 1.76 x 1.6 x
EV / Revenue 0.89 x 2.22 x 2.55 x 3.56 x 2.11 x 2.04 x
EV / EBITDA 13.8 x 32 x 22.4 x 20.7 x 12.9 x 21.5 x
EV / FCF -3.24 x -14.1 x -3.38 x -8.06 x -2.63 x -12.5 x
FCF Yield -30.9% -7.07% -29.6% -12.4% -38% -8.03%
Price to Book 0.71 x 1.9 x 1.59 x 2.41 x 1.3 x 1.27 x
Nbr of stocks (in thousands) 56,833 56,833 56,833 58,833 73,041 73,041
Reference price 2 9,350 28,000 25,200 39,800 24,500 25,000
Announcement Date 3/15/19 3/30/20 3/31/21 1/28/22 3/30/23 3/28/24
1VND in Million2VND
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 804,180 752,014 671,246 703,634 1,015,686 1,143,946
EBITDA 1 51,777 52,255 76,184 120,888 166,302 108,737
EBIT 1 10,752 12,788 47,904 86,781 128,285 70,726
Operating Margin 1.34% 1.7% 7.14% 12.33% 12.63% 6.18%
Earnings before Tax (EBT) 1 20,028 104,733 85,944 110,284 141,542 78,111
Net income 1 12,535 88,474 66,391 85,961 111,641 61,717
Net margin 1.56% 11.76% 9.89% 12.22% 10.99% 5.4%
EPS 2 220.6 1,244 966.2 1,495 1,591 845.0
Free Cash Flow 1 -220,456 -118,140 -505,849 -310,957 -814,492 -187,823
FCF margin -27.41% -15.71% -75.36% -44.19% -80.19% -16.42%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/15/19 3/30/20 3/31/21 1/28/22 3/30/23 3/28/24
1VND in Million2VND
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 182,032 79,505 277,741 166,227 351,945 512,418
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 3.516 x 1.521 x 3.646 x 1.375 x 2.116 x 4.712 x
Free Cash Flow 1 -220,456 -118,140 -505,849 -310,957 -814,492 -187,823
ROE (net income / shareholders' equity) 1.59% 10.3% 7.43% 8.81% 9.59% 4.37%
ROA (Net income/ Total Assets) 0.46% 0.46% 1.7% 3.03% 4.13% 2.02%
Assets 1 2,753,636 19,059,391 3,895,044 2,838,109 2,705,724 3,059,709
Book Value Per Share 2 13,171 14,726 15,863 16,492 18,806 19,610
Cash Flow per Share 2 398.0 255.0 737.0 701.0 724.0 322.0
Capex 1 102,686 10,515 101,948 152,612 233,028 222,874
Capex / Sales 12.77% 1.4% 15.19% 21.69% 22.94% 19.48%
Announcement Date 3/15/19 3/30/20 3/31/21 1/28/22 3/30/23 3/28/24
1VND in Million2VND
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CUU LONG PHARMACEUTICAL Stock Cuu Long Pharmaceutical
+9.20% 78.71M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DCL Stock
  4. Financials Cuu Long Pharmaceutical